Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRI-600
- Development stage
- Preclinical
- Lead developer
- Priavoid
- Modality
- Peptides
01
Overview
PRI-600 is an investigational All-D-Peptide therapeutic currently in the discovery stage, developed by Priavoid. The drug is part of a proprietary platform of D-enantiomeric peptides designed to be highly stable against proteolytic degradation and possess low immunogenicity compared to traditional L-peptides. While the specific molecular target and clinical indication for PRI-600 have not yet been disclosed, Priavoid's research focus is primarily on neurodegenerative disorders involving protein aggregation, such as Alzheimer's disease and Parkinson's disease. The All-D-Peptide modality is intended to directly target and stabilize toxic protein oligomers into non-toxic monomers.
Beyond the preview
Go deeper on PRI-600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRI-600.